Anika Therapeutics
ANIK
123 hedge funds and large institutions have $360M invested in Anika Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 48 reducing their positions, and 13 closing their positions.
928% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $240K
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
12% more capital invested
Capital invested by funds: $321M → $360M (+$39M)
2% more funds holding
Funds holding: 121 → 123 (+2)
9.1% less ownership
Funds ownership: 92.24% → 83.14% (-9.1%)
25% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$5.62M |
| 2 |
Millennium Management
New York
|
+$3.42M |
| 3 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$2.06M |
| 4 |
BlackRock
New York
|
+$1.92M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$14.7M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$9.14M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$5.67M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$3.34M |
| 5 |
CM
Capital Management
Glen Allen,
Virginia
|
-$2.44M |
ANIK Hedge Fund Activity: Q4 2022 in Review
123 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2022, worth a combined $360M — up 12% from $321M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ANIK positions and 13 closed out — a net gain of 3 holders — while 36 added to existing stakes and 48 trimmed.
The largest buyer was Boothbay Fund Management, adding an estimated $5.62M. The largest seller was Morgan Stanley, cutting an estimated $14.7M.
- 123 institutional investors held Anika Therapeutics (ANIK) as of Q4 2022, up from 121 in Q3 2022.
- Funds reported $360M of Anika Therapeutics stock for Q4 2022, up 12% quarter-over-quarter.
- 16 funds opened new Anika Therapeutics positions in Q4 2022 and 13 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q4 2022 was Boothbay Fund Management, an estimated $5.62M added.
- The largest Anika Therapeutics seller in Q4 2022 was Morgan Stanley, an estimated $14.7M sold.
Based on aggregated 13F filings for Q4 2022.